Table 5.
Predicted point estimates and 95% CIs of multiplicative VE for HVCD-DENV-Any endpoint between month 0 and month 72 in the hypothetical CYD14 and CYD15 18–45-y-old and 46–50-y-old cohorts, fixing ρ=ɸ=1
| Data | Age (y) | Approach 1 AT | Approach 2 AT |
|---|---|---|---|
| CYD22* | 18–45 | 59.1 (40.9 to 92.2) | 73.5 (44.7 to 89.0) |
| CYD65-PHL | 18–45 | 62.3 (43.7 to 98.9) | 78.1 (52.3 to 91.5) |
| CYD65-COL | 18–45 | 60.2 (43.9 to 88.7) | 72.2 (47.5 to 86.3) |
| CYD65 | 18–45 | 58.8 (43.9 to 85.9) | 73.2 (48.4 to 87.6) |
| CYD22 and CYD65 | 18–45 | 59.5 (44.0 to 87.2) | 73.4 (48.9 to 87.5) |
| CYD65-PHL | 46–50 | 62.2 (43.4 to 97.6) | 78.4 (52.6 to 91.6) |
| CYD65-COL | 46–50 | 57.2 (40.5 to 81.1) | 69.1 (44.1 to 84.5) |
| CYD65 | 46–50 | 58.8 (43.9 to 85.9) | 73.2 (48.4 to 87.6) |
AT, average titer; HVCD-DENV-Any, hospitalized, symptomatic, virologically confirmed dengue of any serotype; VE, vaccine efficacy.
*
The CYD22 results were also reported in11 and are shown here for comparison.